Claudication: Treatment Options for Femoropopliteal Disease

Progress in Cardiovascular Diseases

Volumn 54, Issue 1, 2011, Pages 41-46

  Schillinger, Martin ^a   Minar, Erich ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Claudication; Femoropopliteal disease; Treatment

Indexed keywords

BUFLOMEDIL; CILOSTAZOL; EVEROLIMUS; NAFTIDROFURYL; PACLITAXEL; PLACEBO; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN E1;

ANKLE BRACHIAL INDEX; ARTERY CALCIFICATION; ARTERY OCCLUSION; ARTICLE; ATHEROSCLEROSIS; BARE METAL STENT; DIARRHEA; DRUG ELUTING STENT; DRUG INDUCED HEADACHE; ENDARTERECTOMY; EXERCISE TOLERANCE; FEMOROPOPLITEAL BYPASS; FEMOROPOPLITEAL DISEASE; HEART PALPITATION; HUMAN; INTERMITTENT CLAUDICATION; MINIMALLY INVASIVE PROCEDURE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RECANALIZATION; RESTENOSIS; STENT; SUPERFICIAL FEMORAL ARTERY; TREADMILL EXERCISE; UNSPECIFIED SIDE EFFECT; VASCULAR PATENCY; WALKING;

ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; ENDOVASCULAR PROCEDURES; EXERCISE THERAPY; FEMORAL ARTERY; HUMANS; INTERMITTENT CLAUDICATION; PATIENT SELECTION; POPLITEAL ARTERY; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASCULAR SURGICAL PROCEDURES;

EID: 79959759062     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2011.04.003     Document Type: Article

References (13)

1. Dormandy J.A., Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000, 31:S1-S296.
2. Norgren L., Hiatt W.R., Dormandy J.A., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45:S5-S67.
3. Regensteiner J., Ware J.J., McCarthy W., et al. Effect of Cilostazol on treadmill walking, community based walking ability and health related quality of life in patients with intermittent claudication due to peripheral arterial disease: a meta analysis of six randomized controlled trials. J Am Geriatric Soc 2002, 50:1939-1946.
4. Lehert P., Comte S., Gamand S., et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994, 23:S48-S52.
5. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. Circulation 2008, 117:816-822. Limbs International Study Group.
6. Reiter M., Bucek R.A., Stümpflen A., et al. Postanoids for intermittent claudication. Cochrane Dataase Syst Rev 2004, CD000986.
7. Schillinger M., Sabeti S., Loewe C., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006, 354:1879-1888.
8. Schillinger M., Sabeti S., Dick P., et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007, 15:2745-2749.
9. Krankenberg H., Schluter M., Steinkamp H.J., et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007, 116:285-292.
10. Kedora J., Hohmann S., Garrett W., et al. Randomized comparison of percutaneous Viabahn stent grafts vs. prosthethic femoropopliteal bypass in the treatment of superficial femoral occlusive disease. J Vasc Surg 2007, 45:10-16.
11. Tepe G., Zeller T., Albrecht T., et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008, 358:689-699.
12. Duda S.H., Pusich B., Richter G., et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-months results. Circulation 2002, 106:1505-1509.
13. Duda S.H., Bosiers M., Lammer J., et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005, 16:331-338.